

NOTES TO THE CONSOLIDATED AND SEPARATE FINANCIAL STATEMENTS continued

for the year ended 30 June 2024

19. COST OF PHARMACEUTICAL PRODUCTS AND FINISHED GOODS

	Group		Company	
	2024 R'000	2023 R'000	2024 R'000	2023 R'000
Opening inventories	444 562	431 764	-	-
Purchases	2 034 793	2 117 585	-	-
Inventories adjustment	-	20 287	-	-
Closing inventories	(449 079)	(444 562)	-	-
Cost of pharmaceutical products and finished goods	2 030 276	2 125 074	-	-
Cost of distribution of pharmaceutical products	71 624	78 376	-	-
TOTAL COST RELATING TO PHARMACEUTICAL PRODUCTS	2 101 900	2 203 450	-	-

20. PROFIT BEFORE TAXATION

Profit before taxation is stated after charging the following items:

	Group		Company	
	2024 R'000	2023 R'000	2024 R'000	2023 R'000
AUDITORS' REMUNERATION (INCLUDED IN "OTHER EXPENSES")	20 112	18 467	4 452	2 613
Audit fees	18 619	17 637	3 525	2 359
Prior period under provision	1 493	830	927	254
DEPRECIATION OF PROPERTY AND EQUIPMENT	94 142	82 976	-	-
Motor vehicles	3 752	3 556	-	-
Computer equipment	56 709	48 218	-	-
Buildings	5 653	4 841	-	-
Furniture and fittings	15 377	14 981	-	-
Property and Equipment	10 984	9 723	-	-
Leasehold improvements	1 667	1 657	-	-
Amortisation of development costs and other intangible assets	192 690	208 823	-	-
Right of use asset depreciation	52 747	65 380	-	-
Share-based payment expense	3 133	17 837	124	695
Bad debt write-off	12 398	16 332	-	-
Expected credit loss allowance	36 482	41 102	-	-
Rent and property costs	107 234	87 479	-	-
Buildings*	104 652	85 831	-	-
Office equipment and furniture*	2 582	1 648	-	-
Repairs and maintenance (included in rent and property costs)	15 816	21 623	-	-
Rent and property costs total	123 050	109 102	-	-
Capitation costs	1 645 000	1 772 982	-	-

* Included in the rent and property cost is short-term leases of 2024: R2 552 000 (2023: R1 648 000) relating to office equipment and furniture 2024: R2 581 000 (2023: R1 648 000).